A Phase 4 interventional study of telmisartan and Losartan in Diabetic Nephropathies and Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-28.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Diabetic Nephropathies with a site in Korea, Republic of — 4 open to participants now, 5 under way, 1 of them phase 3. Diabetic Nephropathies · Korea, Republic of.
Among the 25 studies in Diabetic Nephropathies with a site in Korea, Republic of, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 4, and was the 22nd registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →4 of the 25 studies in Diabetic Nephropathies with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Aptabio Therapeutics, Inc. · Sites in Korea, Republic of
Ages 19+
Walden Biosciences · Sites in Korea, Republic of, United States, Australia and 4 more countries
Ages 18–75
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 233 across the 24 interventional studies, 360 across the 1 observational. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 25 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 1 study filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Nephropathies with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT06962098Aptabio Therapeutics, Inc.Efficacy and Safety Study of Isuzinaxib in Subjects With DKD | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Diabetic Nephropathies with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension
A Multi-center, Randomized, Open-label, Active comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared with Losartan in Patients with Diabetic Nephropathy and Hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: telmisartan
Drug: Losartan
QD, PO
QD, PO
Change rate from baseline in Spot-UACR(Albumin/Creatinine Ratio)
Time frame: 24 weeks after drug administration
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Oct 2025, 30 months after the start.
Of 21 phase 4 interventional studies under Diabetic Nephropathies, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's planned 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telmisartan
Chong Kun Dang Pharmaceutical →